Cancer Med: A domestic multicenter randomized double-blind phase II study showed that Anlotinib (Anlotinib) after-line treatment improved the prognosis of patients with advanced or metastatic esophageal squamous cell carcinoma compared with placebo

Anlotinib is an oral small molecule tyrosine kinase inhibitor (TKI) that targets vascular endothelial growth factor (VEGF) receptors 1, 2 and 3, and fibroblast growth factor (FGF) receptors 1-4.

Anlotinib is an oral small molecule tyrosine kinase inhibitor (TKI) that targets vascular endothelial growth factor (VEGF) receptors 1, 2 and 3, and fibroblast growth factor (FGF) receptors 1-4.

This randomized, double-blind, placebo-controlled Phase II clinical trial was conducted in 13 hospitals in China (ALTER1102, NCT02649361)

This randomized, double-blind, placebo-controlled Phase II clinical trial was conducted in 13 hospitals in China (ALTER1102, NCT02649361)

During the period from January 6, 2016 to May 22, 2018, a total of 196 patients were screened for eligibility

The investigator-assessed median progression-free survival (PFS): 3.

There was no statistical difference in OS between the two groups (HR 1.

There was no significant difference in ORR between the two groups (8/109 (7.

The incidence of treatment-related AEs of any grade in the two groups was 94% and 82%, respectively

In summary, studies have shown that compared with placebo, the use of Anlotinib in previously treated patients with relapsed or metastatic ESCC significantly improved the progression-free survival (PFS)

Original source:

Original source:

Huang J, Xiao J, Fang W, Lu P, Fan Q, Shu Y, Feng J, Zhang S, Ba Y, Zhao Y, Liu Y, Bai C, Bai Y, Tang Y, Song Y, He J.
Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial.
Cancer Med.
2021 Mar;10(5):1681-1689.
doi: 10.
1002/cam4.
3771.
Epub 2021 Feb 14.
PMID: 33586360 ; PMCID: PMC7940231.

Huang J, Xiao J, Fang W, Lu P, Fan Q, Shu Y, Feng J, Zhang S, Ba Y, Zhao Y, Liu Y, Bai C, Bai Y, Tang Y, Song Y, He J.
Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial.
Cancer Med.
2021 Mar;10(5):1681-1689.
doi: 10.
1002/cam4.
3771.
Epub 2021 Feb 14.
PMID: 33586360 ; PMCID: PMC7940231.
Huang J, Xiao J, Fang W, Lu P, Fan Q, Shu Y, Feng J, Zhang S, Ba Y, Zhao Y, Liu Y, Bai C, Bai Y, Tang Y, Song Y, He J.
Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial.
Cancer Med.
2021 Mar;10(5):1681-1689.
doi: 10.
1002/cam4.
3771.
Epub 2021 Feb 14.
PMID: 33586360; PMCID: PMC7940231.


Leave a message here